Fighting cancer is no easy task. This disease is very diverse as well as very dangerous. The medications that are used for fighting this disease takes time to be developed. There is a ton of research that goes into producing such powerful medications and getting the medication approved by the FDA can be frustrating. Dr. Clay Siegall is one of many people that has gotten a drug approved by the FDA, and this drug has gone on to help people all around the world. ADCETRIS is one of the very best cancer-fighting drugs to date. Also referred to as Brentuximab Vedotin, ADCETRIS is leading the charge of modern-day targeted-cancer therapies. In an overall sense, this drug has brought in more than $350 million in revenue for Seattle Genetics.
Dr. Clay Siegall plays an important role at Seattle Genetics in more ways than one. He is the heart and soul of this innovative high-tech company. In other words, Dr. Siegall is the company’s founder as well as its president. Science and innovation goes hand-to-hand here. Dr. Siegall is a firm believer of mixing technology with medicine. The results of this eclectic combination is phenomenal. ADCETRIS is being used in more than 60 different countries across the globe, and it has helped Seattle Genetics’ stock more than double in a span of a few years. By expanding its pipeline, this company is performing clinical trials in medicine for Hodgkin Lymphoma, for Non-Hodgkin Lymphoma, for breast cancer and for urothelial cancer.
Who else can do it any better? Dr. Siegall is a mastermind, and he gets things done on a consistent basis because time is of the essence. This celebrated and well-accomplished doctor has found a recipe for success, and he’s using this recipe to save lives. Dr. Clay Siegall and Seattle Genetics is surely a winning solution.
Eric Lefkofsky, the 47-year old does not like starting new companies. However, Eric and his partner Brad Keywell have built a lucrative tech business in Chicago. At his stage in his career Eric Lefkofsky priority is not to venture into startups; it was only after his wife got cancer that that he was compelled to start Tempus.
Eric and Keywell provided a better solution to cancer by introducing a data-based method to cancer management. The two started tempus which masters a patient’s growth and proposes a treatment design to battle it. Lefkofsky has his main focus on Tempus beyond his previous projects. He refers to Tempus as a great solution to treatment of cancer by integrating modern technology.
According to Eric, he intends to run the company from his own funds so he doesn’t have to waste time looking for funding. His dislike in starting companies result from the pressure involved. Thus, starting tempus was mainly to solve a problem in his life; his wife’s cancer. He felt the cancer medical industry was not doing enough to combat cancer from his interaction with cancer patients.
Tempus stores clinical histories from previous patients to help physicians treat similar cases. The organization has partnered with different healthcare companies including the Mayo Clinic, the University of Chicago and University of Michigan. The institutions send cancer patients to Tempus synchronize them and send reports back to the oncologists.
He proudly speaks of Tempus having to solve serious medical problems. At his age, he feels he has accomplished a major project through Tempus. Eric says that the success of his company took time to show. He measures his success by how much patients and physician gain from his services.
Lefkofsky terms company as the best music he had ever made. His company has gained popularity from cancer centers. He is most assured that Tempus will be his most successful act to date.
Eric Lefkofsky is the CEO of Tempus, the company that established a technology-based approach to cancer treatment.He is a co-founder of Lightbank, which invests in disrupting technology. Eric also serves as the Chairman of Groupon, an e-commerce site.
He is a co-founder of Uptake Technologies, an analytics program for industries. Also, he is a partner in Echo Global Logistics, a tech-based transport company and InnerWorkings dealing with print and advertising solutions.